KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Raw Materials (2016 - 2025)

Astrazeneca has reported Raw Materials over the past 11 years, most recently at $1.9 billion for Q4 2025.

  • Quarterly results put Raw Materials at $1.9 billion for Q4 2025, up 24.71% from a year ago — trailing twelve months through Dec 2025 was $1.9 billion (up 24.71% YoY), and the annual figure for FY2025 was $1.9 billion, up 24.71%.
  • Raw Materials for Q4 2025 was $1.9 billion at Astrazeneca, up from $1.5 billion in the prior quarter.
  • Over the last five years, Raw Materials for AZN hit a ceiling of $1.9 billion in Q4 2025 and a floor of $1.4 billion in Q4 2022.
  • Median Raw Materials over the past 5 years was $1.5 billion (2023), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Raw Materials: surged 39.06% in 2021 and later decreased 18.97% in 2022.
  • Astrazeneca's Raw Materials stood at $1.8 billion in 2021, then decreased by 18.97% to $1.4 billion in 2022, then grew by 7.67% to $1.5 billion in 2023, then decreased by 2.74% to $1.5 billion in 2024, then rose by 24.71% to $1.9 billion in 2025.
  • The last three reported values for Raw Materials were $1.9 billion (Q4 2025), $1.5 billion (Q4 2024), and $1.5 billion (Q4 2023) per Business Quant data.